Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 21:2020:8861435.
doi: 10.1155/2020/8861435. eCollection 2020.

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection

Elcin Suren  1 , Ersan Cetinkaya  1 , Mustafa Kalayci  1 , Sariye Elif Özyazıcı Özkan  2 , Mehmet Fatih Kucuk  1 , Muhammet Kazim Erol  1
Affiliations
Case Reports

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection

Elcin Suren et al. Case Rep Ophthalmol Med. .

Abstract

We report the case of a male infant who had an intravitreal anti-VEGF (aflibercept) injection for the treatment of retinopathy of prematurity at 35-week postmenstrual age. Four days following the injection, retinal imaging demonstrated a yellowish gray blurred mass that extended into the vitreous in the right eye, and the vitreous body was blurred. After two days, despite starting endophthalmitis treatment, there was still no improvement in the retinal lesion. Due to the worsening of the clinical signs, we decided to perform 25-gauge lens-sparing pars plana vitrectomy.

PubMed Disclaimer

Conflict of interest statement

We declare that there is no financial support or relationships that may pose a conflict of interest. Finally, there is no conflict of interest in connection with this submitted article.

Figures

Figure 1
Figure 1
Yellowish-gray blurred mass that extended into the vitreous.
Figure 2
Figure 2
Favorable anatomic result was achieved four weeks after the pars plana vitrectomy.
See this image and copyright information in PMC

References

    1. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Archives of Ophthalmology. 2005;123(7):991–999. doi: 10.1001/archopht.123.7.991. - DOI - PubMed
    1. Rezai K. A. Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity. Archives of Ophthalmology. 2005;123(5):621–626. doi: 10.1001/archopht.123.5.621. - DOI - PubMed
    1. Chung E. J., Kim J. H., Ahn H. S., Koh H. J. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Graefe’s Arch Clin Exp Ophthalmol. 2007;245(11):1727–1730. doi: 10.1007/s00417-007-0661-y. - DOI - PubMed
    1. Wang J., Xiang D. Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: a case report. Experimental and Therapeutic Medicine. 2017;13(6):3563–3566. doi: 10.3892/etm.2017.4406. - DOI - PMC - PubMed
    1. Chandra P., Kumawat D., Tewari R., Azimeera S. Post-ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity. Indian Journal of Ophthalmology. 2019;67(6):967–969. doi: 10.4103/ijo.IJO_884_17. - DOI - PMC - PubMed

Publication types

LinkOut - more resources